Protalix BioTherapeutics (NYSE:PLX) Trading Up 3.7%

Protalix BioTherapeutics, Inc. (NYSE:PLX – Get Rating) shares were up 3.7% during trading on Tuesday . The company traded as high as $1.96 and last traded at $1.94. Approximately 1,306,325 shares were traded during trading, an increase of 45% from the average daily volume of 900,338 shares. The stock had previously closed at $1.87.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Protalix BioTherapeutics in a report on Friday, December 16th. They set a “hold” rating on the stock.

Protalix BioTherapeutics Trading Up 3.7 %

The firm has a market cap of $96.52 million, a price-to-earnings ratio of -6.47 and a beta of 1.51. The stock has a 50-day moving average of $1.53 and a 200-day moving average of $1.25.

Protalix BioTherapeutics Company Profile

(Get Rating)

Protalix Biotherapeutics, Inc is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.